Form 4: Atossa Therapeutics Director Stephen J. Galli Acquires Stock Options

Director Stephen J. Galli acquired stock options in Atossa Therapeutics, Inc. on June 27, 2024.

Summary

• Stephen J. Galli, a director of Atossa Therapeutics, Inc., filed a Form 4 on July 1, 2024, reporting a transaction.
• On June 27, 2024, Galli acquired 125,000 stock options with an exercise price of $1.05.
• These options vest quarterly over 12 months, contingent upon Galli's continued service.
• The exercise price of $1.05 is based on the closing stock price on June 26, 2024.
• Following the transaction, Galli directly owns 125,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard stock option grant to a director. It indicates confidence but doesn't provide significant new information.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedule aligns the director's interests with the long-term success of the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Stakeholder Impact

• The stock option grant could potentially incentivize the director to work towards increasing shareholder value.

Key Dates